NCT00217672View on ClinicalTrials.gov

Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

November 30, 2010

Conditions
Breast Cancer
Interventions
BIOLOGICAL

bevacizumab

Patients receive bevacizumab 15 mg/kg intravenously (I.V.) every 3 weeks until disease progression, unacceptable toxicity, or consent withdrawal.

DRUG

Docetaxel

docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.

Trial Locations (1)

90095-1781

Jonsson Comprehensive Cancer Center at UCLA, Los Angeles

All Listed Sponsors
collaborator

University of California, Los Angeles

OTHER

lead

Translational Oncology Research International

OTHER

NCT00217672 - Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer | Biotech Hunter | Biotech Hunter